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Bridging the gaps between cancer genomics, computational solutions and 
healthcare delivery 
 
Abstract (89 words) 
 
For learnings from academic research to impact health outcomes, they must be embedded 
into routine clinical practice. Research innovations such as the human genome project, next-
generation sequencing technology and the International Cancer Genome Consortium (ICGC) 
have provided a wealth of knowledge describing the contribution of the genome to cancer 
development, disease behaviour, treatment response and clinical outcome. These learnings 
have the potential to improve survival for cancer patients. Realisation of this potential 
requires bridging of the translation gap to unlock the clinical, as well as the biological, 
meaning of genomics. 
 
Main text (1,287 words) 
 
Precision medicine is the matching of individual patients to treatments that maximise 
therapeutic benefit. Genomics, alongside transcriptomics, epigenetics and other ‘omics, is a 
key enabler of this process. Advances in genomics to date have largely been restricted to a 
single-gene single-drug paradigm, as exemplified by EGFR inhibitor therapy for EGFR-mutant 
lung cancers. Unlocking the true power of genomics requires integration of comprehensive 
genomic profiling with clinical and outcome data to build datasets comprising many 
thousands, if not millions, of patients, thus providing a platform for leveraging artificial 
intelligence-driven analytics. 
 
Comprehensive genomic profiling - the identification and integrated analysis of all relevant 
genomic features in a cancer - has demonstrated utility in disease classification, prognosis, 
and prediction of both treatment response and patient outcomes. Early examples from 
haemato-oncology highlight this potential of genomics to impact patient care in myriad ways. 
Diffuse large B-cell lymphoma, the most common haematological cancer, can be split into 
subtypes with different genomic profiles and clinical outcomes, suggesting benefits from 
differentiated treatment strategies [1]. Genomics-based classification of myeloproliferative 
neoplasms improves outcome prediction and facilitates patient-tailored therapy [2]. In acute 
myeloid leukaemia, models trained on knowledge banks of thousands of patients’ data can 
predict the likelihood of disease remission and better identify those benefitting from stem 
cell transplantation versus consolidation chemotherapy [3]. These scenarios are driving a shift 
in haemato-oncology from the historical phenotype-based approaches to patient 
management to genomics-based treatment algorithms. Recent studies in breast, prostate and 
colorectal tumours demonstrate similar predictive and prognostic significance of genomic 
data in solid tumours, as well as highlighting how co-occurrence of genomic drivers impacts 
tumour behaviour [4–6]. 
 
Whilst the majority of clinical studies to date have focussed on analysis of coding variants in 
a limited number of genes [7], a recent study integrated comprehensive multi-parameter 
genomic profiling with clinical outcomes to predict treatment response in testicular cancer 
[8].  This work highlights a pressing need for large projects in other cancer types which 
integrate all cancer-relevant genomic variants with key clinical outcomes. Accumulating 
evidence indicates that genomic data need to be comprehensive for both variant type (copy 
number, structural variants, genomic signatures etc) and genomic feature type (splicing, 
regulatory etc) in order to train classifiers and fully unlock clinical utility. The current lack of 
large solid tumour genomic datasets with associated clinical data is creating a chicken-and-
egg scenario, where the utility and evidence around the benefits of comprehensive molecular 
profiling for cancer patients is both required for, and yet can only be generated by, 
widespread clinical adoption. Only the adoption of comprehensive genomic profiling into 
healthcare systems (and eventually global integration of data) will generate enough multi-
dimensional data from sufficient patients to power substantial progress within our 
generation, yet healthcare systems often only adopt genomic profiling once there is evidence 
of immediate clinical utility to justify the cost. 
 
International research efforts have identified around 600 genomic drivers that are relevant 
to cancer development, diagnosis, prognosis or response prediction [9]. While some genes, 
such as TP53, are mutated in a large proportion of tumours, many cancer drivers are found in 
only a few percent of cases. Cancers typically harbour 4-5 driver variants each [9], giving rise 
to almost limitless combinations of drivers, both within cancer types and between the 200 or 
so different cancers currently recognised [10]. This variability means that thousands or tens 
of thousands of cases are needed per cancer type, to identify, and power analyses of the 
prognostic effect of, low frequency cancer genes, or to predict differences in outcome with 
sufficient confidence and precision to support clinical decision making. The complexity of 
cancer biology and genomics explains why a one-size-fits-all approach to treatment fails to 
deliver benefits for many individuals and makes the case for a move towards a precision 
medicine approach, where biomarkers are used to match patients to appropriate therapies.  
 
Powering the clinical trials needed to assess precision therapeutics again requires many 
thousands of cancer patients with genomic data and progress is painfully slow with current 
strategies for obtaining this. Since comprehensive genomic profiling is not currently standard 
of care for most cancers or in most healthcare systems, trials of biomarker-directed 
therapeutics face a major challenge in finding patients. There were over 700 cancer drugs in 
late phase clinical trials in 2017, with a third of clinical trials using biomarker stratification 
[11]. For a cancer with the prevalence of pancreatic cancer - circa 10,000 cases per year in the 
UK - it would take 2 years and around $1.4 million in screening costs, using commercially 
available genomic assays, to find enough patients for a phase 1 trial using a biomarker with 
10% prevalence given typical clinical trial recruitment rates. This time and effort severely 
limits the number of conventional clinical trials that can be run and contributes to the 
spiralling costs of those drugs that do ultimately gain approval. A very large number of such 
trials is required to test all new cancer drugs with genomic biomarkers, along with the 
exponential number of drug combinations and scheduling/dosing strategies. 
 
We are currently at an impasse: academic researchers are moving away from molecular 
characterisation of cancers, with the focus shifting instead to prevention and early detection; 
industry is struggling to find adequate patients to power precision medicine drug trials; and 
healthcare systems are often choosing to implement limited scope tests covering small 
numbers of biomarkers rather than commissioning comprehensive genomic profiling.  
 
While current clinical utility alone may not be sufficient to justify the routine use of 
comprehensive genomic profiling, this approach delivers a multitude of additional benefits by 
enabling self-learning healthcare systems [12]. A self-learning healthcare system is one that 
uses the data it generates to feed back into a cycle of continual updating and improvement. 
Deploying comprehensive genomic profiling for all patients as standard of care is the fastest 
way to generate real-world clinical-genomic datasets of sufficient size to power the self-
learning process. Such datasets can be leveraged to develop the knowledge bases and artificial 
intelligence-powered statistical models that have already demonstrated utility in 
haematological malignancies. These learnings can then, in turn, shape clinical guidelines and 
routine oncology practice. Delivery within public healthcare systems would ensure the data is 
owned by patients and their doctors. This would facilitate data sharing/aggregation and 
prevent the fracturing of data into small underpowered siloes, whilst still enabling academic 
research and revenue-generating commercial access from the soon-to-be $504 billion digital 
health sector [13]. 
 
Comprehensive genomic profiling of all cancer patients would, in effect, turn the entire 
oncology patient population into a platform trial by providing a surrogate master protocol 
with molecular screening. This would reduce the set-up time, patient recruitment time and 
costs for trials of biomarker-driven therapies and hence accelerate therapeutic development. 
While clinical trials may historically have been seen as research rather than healthcare, they 
are the only therapeutic option for many patients with advanced cancer and are increasingly 
viewed as a desirable part of routine management [14,15]. The vast majority of those living 
with cancer are willing to participate in a clinical trial [16]. In addition, commercially 
sponsored clinical trials are revenue generating for public healthcare systems, delivering an 
average return of £6,658 ($8,587) per patient [17] alongside an average pharmacy saving of 
£5,250 ($6,771). 
 
At present, the lack of large datasets integrating comprehensive genomic profiling with 
treatment response and clinical outcomes is a significant roadblock in the path to unlocking 
the full clinical utility of genomics in cancer. Deploying comprehensive genomic profiling for 
cancer patients removes this impasse and provides a win-win-win for healthcare systems, 
drug developers and patients. The first healthcare system to successfully deliver genomic data 
and clinical data in secure and interoperable formats will reap the largest rewards, both from 
the investment it will attract, the development opportunities it will provide, and by supplying 
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